Antimetabolite use in revising failing filtering blebs.
This article evaluates the efficacy of a subconjunctival injection of mitomycin-C (MMC) followed by needling of the scar tissue to restore bleb function. By means of preoperative ultrasonic biomicroscopy, all the eyes in this study were categorized into one of three groups: Group I (bleb present), Group II (minimal bleb), and Group III (no bleb present). This classification was carried out to try to control for differences in bleb appearance that may correlate with bleb function.
Kapetansky
F M
FM
Ohio State University, Columbus, OH, USA.
Kapetansky
S D
SD
D000869:Anterior Eye Segment / Q000000981:diagnostic imaging; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005355:Fibrosis / Q000188:drug therapy / Q000601:surgery; D005902:Glaucoma, Open-Angle / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000502:physiology; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D012086:Reoperation; D012599:Sclerostomy; D017211:Treatment Failure; D014463:Ultrasonography
D000964:Antimetabolites, Antineoplastic; D016685:Mitomycin